Showing results (1-10 of 56) with videos related to

Sort By:
Pageof 6
The Oncologist|May 2, 2007
Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancerMaartje Los, Jeanine M L Roodhart, Emile E Voest
Trends in Cancer|February 17, 2020
Colorectal Cancer Modeling with Organoids: Discriminating between Oncogenic RAS and BRAF VariantsJasmin B Post, Jeanine M L Roodhart, Hugo J G Snippert
Current Clinical Pharmacology|April 22, 2010
Vascular disrupting agents (VDAs) in anticancer therapyLaura G M Daenen, Jeanine M L Roodhart, Yuval Shaked, et al.
International Journal of Cancer|July 12, 2018
Detection of endogenously circulating mesenchymal stem cells in human cancer patientsDaphne L van der Velden, Julia M Houthuijzen, Jeanine M L Roodhart, et al.
NPJ Precision Oncology|April 13, 2021
Patient-derived organoids as a predictive biomarker for treatment response in cancer patientsG Emerens Wensink, Sjoerd G Elias, Jasper Mullenders, et al.
European Journal of Cancer (Oxford, England : 1990)|July 18, 2024
Survival and patient-reported outcomes of real-world high-risk stage II and stage III colon cancer patients after reduction of adjuvant CAPOX duration from 6 to 3 monthsIngrid A Franken, Frederieke H van der Baan, Geraldine R Vink, et al.
Cancer Research|October 7, 2011
Chemotherapy enhances metastasis formation via VEGFR-1-expressing endothelial cellsLaura G M Daenen, Jeanine M L Roodhart, Miranda van Amersfoort, et al.
European Journal of Cancer (Oxford, England : 1990)|October 5, 2024
Efficacy and safety in early-phase clinical trials for refractory colorectal cancer: A meta-analysisLidwien P Smabers, Maarten A Huismans, Niels van Nieuwenhuijzen, et al.
The Journal of Urology|June 19, 2012
Radio frequency ablation combined with interleukin-2 induces an antitumor immune response to renal cell carcinoma in a murine modelStephanie G C Kroeze, Laura G M Daenen, Maarten W Nijkamp, et al.
British Journal of Cancer|May 20, 2024
Efficacy-effectiveness analysis on survival in a population-based real-world study of BRAF-mutated metastatic colorectal cancer patients treated with encorafenib-cetuximabKoen Zwart, Sietske C M W van Nassau, Frederieke H van der Baan, et al.
Pageof 6